nach oben

World Journal of Urology

Erschienen in:

23.06.2016 | Topic Paper

Vitamins, metabolomics, and prostate cancer

verfasst von: Alison M. Mondul, Stephanie J. Weinstein, Demetrius Albanes

Erschienen in: World Journal of Urology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

How micronutrients might influence risk of developing adenocarcinoma of the prostate has been the focus of a large body of research (especially regarding vitamins E, A, and D). Metabolomic profiling has the potential to discover molecular species relevant to prostate cancer etiology, early detection, and prevention, and may help elucidate the biologic mechanisms through which vitamins influence prostate cancer risk.

Methods

Prostate cancer risk data related to vitamins E, A, and D and metabolomic profiling from clinical, cohort, and nested case–control studies, along with randomized controlled trials, are examined and summarized, along with recent metabolomic data of the vitamin phenotypes.

Results

Higher vitamin E serologic status is associated with lower prostate cancer risk, and vitamin E genetic variant data support this. By contrast, controlled vitamin E supplementation trials have had mixed results based on differing designs and dosages. Beta-carotene supplementation (in smokers) and higher circulating retinol and 25-hydroxy-vitamin D concentrations appear related to elevated prostate cancer risk. Our prospective metabolomic profiling of fasting serum collected 1–20 years prior to clinical diagnoses found reduced lipid and energy/TCA cycle metabolites, including inositol-1-phosphate, lysolipids, alpha-ketoglutarate, and citrate, significantly associated with lower risk of aggressive disease.

Conclusions

Several active leads exist regarding the role of micronutrients and metabolites in prostate cancer carcinogenesis and risk. How vitamins D and A may adversely impact risk, and whether low-dose vitamin E supplementation remains a viable preventive approach, require further study.

Nicholson JK, Lindon JC (2008) Systems biology: metabolomics. Nature 455(7216):1054–1056CrossRefPubMed

O’Connell TM (2012) Recent advances in metabolomics in oncology. Bioanalysis 4(4):431–451CrossRefPubMed

Office of Dietary Supplements N (2015) Vitamin E fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminEHealthProfessional/. Accessed 22 June 2016

Wagner KH, Kamal-Eldin A, Elmadfa I (2004) Gamma-tocopherol—an underestimated vitamin? Ann Nutr Metab 48(3):169–188CrossRefPubMed

Brigelius-Flohe R, Kelly FJ, Salonen JT, Neuzil J, Zingg JM, Azzi A (2002) The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr 76(4):703–716PubMed

Ricciarelli R, Zingg JM, Azzi A (2001) Vitamin E: protective role of a Janus molecule. FASEB J 15(13):2314–2325CrossRefPubMed

The ATBC Cancer Prevention Study Group (1994) The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 4(1):1–10

Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90(6):440–446CrossRefPubMed

The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330(15):1029–1035CrossRef

10.

Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR (2005) Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293(11):1338–1347CrossRefPubMed

11.

Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Sesso HD, Buring JE (2009) Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA 301(1):52–62CrossRefPubMed

12.

Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD III, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin e cancer prevention trial (SELECT). JAMA 301(1):39–51CrossRefPubMed

13.

Klein E, Thompson I, Tangen C, Crowley J, Lucia M, Goodman P, Minasian L, Ford L, Parnes H, Gaziano J, Karp D, Lieber M, Walther P, Klotz L, Parsons J, Chin J, Darke A, Lippman S, Goodman G, Meyskens F, Baker L (2011) Vitamin E and the risk of prostate cancer. The selenium and vitamin e cancer prevention trial (SELECT). JAMA 306(14):1549–1556CrossRefPubMedPubMedCentral

14.

Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S, Estaquio C, Hercberg S (2005) Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 116(2):182–186CrossRefPubMed

15.

Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):23–33CrossRef

16.

Gann PH (2009) Randomized trials of antioxidant supplementation for cancer prevention: first bias, now chance—next, cause. JAMA 301(1):102–103. doi:10.1001/jama.2008.863 CrossRefPubMed

17.

Cheng T, Barnett M, Kristal A, Ambrosone C, King I, Thornquist M, Goodman G, Neuhouser M (2011) Genetic variation in myeloperoxidase modifies the association of serum alpha-tocopherol with aggressive prostate cancer among current smokers. J Nutr 141(9):1731–1737CrossRefPubMedPubMedCentral

18.

Goodman GE, Schaffer S, Omenn GS, Chen C, King I (2003) The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiol Biomark Prev 12(6):518–526

19.

Eichholzer M, Stahelin HB, Gey KF, Ludin E, Bernasconi F (1996) Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 66(2):145–150CrossRefPubMed

20.

Rodriguez C, Jacobs EJ, Mondul AM, Calle EE, McCullough ML, Thun MJ (2004) Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomark Prev 13(3):378–382

21.

Weinstein SJ, Wright ME, Pietinen P, King I, Tan C, Taylor PR, Virtamo J, Albanes D (2005) Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst 97(5):396–399CrossRefPubMed

22.

Watters JL, Gail MH, Weinstein SJ, Virtamo J, Albanes D (2009) Associations between alpha-tocopherol, beta-carotene, and retinol and prostate cancer survival. Cancer Res 69(9):3833–3841. doi:10.1158/0008-5472.CAN-08-4640 CrossRefPubMedPubMedCentral

23.

Weinstein SJ, Wright ME, Lawson KA, Snyder K, Mannisto S, Taylor PR, Virtamo J, Albanes D (2007) Serum and dietary vitamin E in relation to prostate cancer risk. Cancer Epidemiol Biomark Prev 16(6):1253–1259CrossRef

24.

Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL (1999) Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomark Prev 8(10):893–899

25.

Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ (1999) Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 59(6):1225–1230PubMed

26.

Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, Albanes D, Andriole GL, Urban DA, Peters U (2006) Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 98(4):245–254CrossRefPubMed

27.

Peters U, Littman AJ, Kristal AR, Patterson RE, Potter JD, White E (2008) Vitamin E and selenium supplementation and risk of prostate cancer in the vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control 19(1):75–87CrossRefPubMed

28.

Wright ME, Weinstein SJ, Lawson KA, Albanes D, Subar AF, Dixon LB, Mouw T, Schatzkin A, Leitzmann MF (2007) Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiol Biomark Prev 16(6):1128–1135CrossRef

29.

Gill JK, Franke AA, Steven MJ, Cooney RV, Wilkens LR, Le ML, Goodman MT, Henderson BE, Kolonel LN (2009) Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control 20(7):1161–1171. doi:10.1007/s10552-009-9304-4 CrossRefPubMedPubMedCentral

30.

Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E (2007) Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European prospective investigation into cancer and nutrition study. Am J Clin Nutr 86(3):672–681PubMed

31.

Key TJ, Appleby PN, Travis RC, Albanes D, Alberg AJ, Barricarte A, Black A, Boeing H, Bueno-de-Mesquita HB, Chan JM, Chen C, Cook MB, Donovan JL, Galan P, Gilbert R, Giles GG, Giovannucci E, Goodman GE, Goodman PJ, Gunter MJ, Hamdy FC, Heliovaara M, Helzlsouer KJ, Henderson BE, Hercberg S, Hoffman-Bolton J, Hoover RN, Johansson M, Khaw KT, King IB, Knekt P, Kolonel LN, Le ML, Mannisto S, Martin RM, Meyer HE, Mondul AM, Moy KA, Neal DE, Neuhouser ML, Palli D, Platz EA, Pouchieu C, Rissanen H, Schenk JM, Severi G, Stampfer MJ, Tjonneland A, Touvier M, Trichopoulou A, Weinstein SJ, Ziegler RG, Zhou CK, Allen NE (2015) Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. Am J Clin Nutr 102(5):1142–1157. doi:10.3945/ajcn.115.114306 CrossRefPubMedPubMedCentral

32.

Major JM, Yu K, Wheeler W, Zhang H, Cornelis MC, Wright ME, Yeager M, Snyder K, Weinstein SJ, Mondul A, Eliassen H, Purdue M, Hazra A, McCarty CA, Hendrickson S, Virtamo J, Hunter D, Chanock S, Kraft P, Albanes D (2011) Genome-wide association study identifies common variants associated with circulating vitamin E levels. Hum Mol Genet. doi:10.1093/hmg/ddr296

33.

Major JM, Yu K, Weinstein SJ, Berndt SI, Hyland PL, Yeager M, Chanock S, Albanes D (2014) Genetic variants reflecting higher vitamin E status in men are associated with reduced risk of prostate cancer. J Nutr 144(5):729–733. doi:10.3945/jn.113.189928 CrossRefPubMedPubMedCentral

34.

Bauer SR, Richman EL, Sosa E, Weinberg V, Song X, Witte JS, Carroll PR, Chan JM (2013) Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence. Prostate 73(16):1786–1795. doi:10.1002/pros.22717 CrossRefPubMed

35.

Wright ME, Peters U, Gunter MJ, Moore SC, Lawson KA, Yeager M, Weinstein SJ, Snyder K, Virtamo J, Albanes D (2009) Association of variants in two vitamin E transport genes with circulating vitamin e concentrations and prostate cancer risk. Cancer Res 69(4):1429–1438CrossRefPubMedPubMedCentral

36.

Ross AC (1999) Vitamin A and retinoids. In: Shils ME, Olson JA, Shike M, Ross AC (eds) Modern nutrition in health and disease, 9th edn. Lippincott Williams & Wilkins, Baltimore, pp 305–327

37.

Peehl DM, Feldman D (2003) The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer 10(2):131–140CrossRefPubMed

38.

Mondul AM, Watters JL, Mannisto S, Weinstein SJ, Snyder K, Virtamo J, Albanes D (2011) Serum retinol and risk of prostate cancer. Am J Epidemiol 173(7):813–821. doi:10.1093/aje/kwq429 CrossRefPubMedPubMedCentral

39.

Office of Dietary Supplements N (2015) Vitamin A fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminAHealthProfessional/. Accessed 22 June 2016

40.

Krinsky NI, Johnson EJ (2005) Carotenoid actions and their relation to health and disease. Mol Asp Med 26(6):459–516. doi:10.1016/j.mam.2005.10.001 CrossRef

41.

Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S, Cherniack MG, Brodkin CA, Hammar S (1996) Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial. J Natl Cancer Inst 88(21):1550–1559CrossRefPubMed

42.

Cook NR, Le IM, Manson JE, Buring JE, Hennekens CH (2000) Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians’ Health Study (United States). Cancer Causes Control 11(7):617–626CrossRefPubMed

43.

Wright ME, Groshong SD, Husgafvel-Pursiainen K, Genova E, Lucia MS, Wolff H, Virtamo J, Albanes D (2010) Effects of beta-carotene supplementation on molecular markers of lung carcinogenesis in male smokers. Cancer Prev Res 3(6):745–752. doi:10.1158/1940-6207.CAPR-09-0107 CrossRef

44.

Coates RJ, Weiss NS, Daling JR, Morris JS, Labbe RF (1988) Serum levels of selenium and retinol and the subsequent risk of cancer. Am J Epidemiol 128(3):515–523CrossRefPubMed

45.

Cook NR, Stampfer MJ, Ma J, Manson JE, Sacks FM, Buring JE, Hennekens CH (1999) Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer 86(9):1783–1792. doi:10.1002/(SICI)1097-0142(19991101)86:9<1783:AID-CNCR21>3.0.CO;2-N CrossRefPubMed

46.

Nash SH, Till C, Song X, Lucia MS, Parnes HL, Thompson IM Jr, Lippman SM, Platz EA, Schenk J (2015) Serum retinol and carotenoid concentrations and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev 24(10):1507–1515. doi:10.1158/1055-9965.EPI-15-0394 CrossRef

47.

Wang Y, Cui R, Xiao Y, Fang J, Xu Q (2015) Effect of carotene and lycopene on the risk of prostate cancer: a systematic review and dose-response meta-analysis of observational studies. PLoS ONE 10(9):e0137427. doi:10.1371/journal.pone.0137427 CrossRefPubMedPubMedCentral

48.

Ferrucci L, Perry JR, Matteini A, Perola M, Tanaka T, Silander K, Rice N, Melzer D, Murray A, Cluett C, Fried LP, Albanes D, Corsi AM, Cherubini A, Guralnik J, Bandinelli S, Singleton A, Virtamo J, Walston J, Semba RD, Frayling TM (2009) Common variation in the beta-carotene 15,15′-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. Am J Hum Genet 84(2):123–133. doi:10.1016/j.ajhg.2008.12.019 CrossRefPubMedPubMedCentral

49.

Mondul AM, Yu K, Wheeler W, Zhang H, Weinstein SJ, Major JM, Cornelis MC, Mannisto S, Hazra A, Hsing AW, Jacobs KB, Eliassen H, Tanaka T, Reding DJ, Hendrickson S, Ferrucci L, Virtamo J, Hunter DJ, Chanock SJ, Kraft P, Albanes D (2011) Genome-wide association study of circulating retinol levels. Hum Mol Genet 20(23):4724–4731. doi:10.1093/hmg/ddr387 CrossRefPubMedPubMedCentral

50.

IARC (2009) Vitamin D and cancer. Lyon, France

51.

Yin L, Raum E, Haug U, Arndt V, Brenner H (2009) Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol 33(6):435–445CrossRefPubMed

52.

Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P (2011) Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 128(6):1414–1424. doi:10.1002/ijc.25439 CrossRefPubMed

53.

Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L, Bekkering GE, Fraser WD, Sterne JA, Metcalfe C (2011) Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 22(3):319–340. doi:10.1007/s10552-010-9706-3 CrossRefPubMed

54.

Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN (2010) Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer 46(5):932–936CrossRefPubMedPubMedCentral

55.

Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjonneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Kroger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, Palli D, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larranaga N, Gonzalez CA, Arguelles MV, Sanchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ (2009) Serum vitamin D and risk of prostate cancer in a case–control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol 169(10):1223–1232CrossRefPubMedPubMedCentral

56.

Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB (2008) Serum vitamin D concentration and prostate cancer risk: a nested case–control study. J Natl Cancer Inst 100(11):796–804CrossRefPubMedPubMedCentral

57.

Tuohimaa P, Tenkanen L, Syvala H, Lumme S, Hakulinen T, Dillner J, Hakama M (2007) Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomark Prev 16(2):302–307CrossRef

58.

Baron JA, Beach M, Wallace K, Grau MV, Sandler RS, Mandel JS, Heber D, Greenberg ER (2005) Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomark Prev 14(3):586–589. doi:10.1158/1055-9965.EPI-04-0319 CrossRef

59.

Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E (2004) Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15(3):255–265CrossRefPubMed

60.

Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, Hakama M (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case–control study in the Nordic countries. Int J Cancer 108(1):104–108CrossRefPubMed

61.

Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW (1995) Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6(3):235–239CrossRefPubMed

62.

Albanes D, Mondul AM, Yu K, Parisi D, Horst RL, Virtamo J, Weinstein SJ (2011) Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case–control study. Cancer Epidemiol Biomark Prev 20(9):1850–1860. doi:10.1158/1055-9965.EPI-11-0403 CrossRef

63.

Weinstein SJ, Mondul AM, Kopp W, Rager H, Virtamo J, Albanes D (2013) Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer 132(12):2940–2947. doi:10.1002/ijc.27969 CrossRefPubMed

64.

Xu Y, Shao X, Yao Y, Xu L, Chang L, Jiang Z, Lin Z (2014) Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol 140(9):1465–1477. doi:10.1007/s00432-014-1706-3 CrossRefPubMed

65.

Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, Torkko KC, Kristal AR, Peters U, Neuhouser ML (2014) Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev 23(8):1484–1493. doi:10.1158/1055-9965.EPI-13-1340 CrossRef

66.

Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA (2014) Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E cancer prevention trial. Cancer Epidemiol Biomark Prev 23(8):1494–1504. doi:10.1158/1055-9965.EPI-14-0115 CrossRef

67.

McCullough ML, Bostick RM, Mayo TL (2009) Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 29:111–132CrossRefPubMed

68.

Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, Jacobs EJ, Ascherio A, Helzlsouer K, Jacobs KB, Li Q, Weinstein SJ, Purdue M, Virtamo J, Horst R, Wheeler W, Chanock S, Hunter DJ, Hayes RB, Kraft P, Albanes D (2010) Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 19(13):2739–2745. doi:10.1093/hmg/ddq155 CrossRefPubMedPubMedCentral

69.

Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O’Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung CL, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen AL, Zhai G, Macdonald HM, Forouhi NG, Loos RJ, Reid DM, Hakim A, Dennison E, Liu Y, Power C, Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon M, Foroud T, Harris TB, Hofman A, Jansson JO, Cauley JA, Uitterlinden AG, Gibson Q, Jarvelin MR, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, Dupuis J, Hypponen E, Spector TD (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376(9736):180–188. doi:10.1016/S0140-6736(10)60588-0 CrossRefPubMedPubMedCentral

70.

Mondul AM, Shui IM, Yu K, Travis RC, Stevens VL, Campa D, Schumacher F, Ziegler RG, Bueno-de-Mesquita HB, Berndt SI, Crawford ED, Gapstur SM, Gaziano JM, Giovannucci E, Haiman C, Henderson BE, Hunter DJ, Johansson M, Key TJ, Le ML, Lindstrom S, McCullough M, Navarro C, Overvad K, Palli D, Purdue MP, Stampfer MJ, Weinstein SJ, Willett W, Yeager M, Chanock SJ, Trichopoulos D, Kolonel LN, Kraft P, Albanes D (2013) Genetic variation in the vitamin D pathway in relation to risk of prostate cancer—results from breast and prostate cancer cohort consortium (BPC3). Cancer Epidemiol Biomark Prev. doi:10.1158/1055-9965.EPI-13-0007-T

71.

Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85(6):1586–1591PubMed

72.

Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O’Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L, Prentice RL, Robbins J, Rohan TE, Sarto GE, Sharma S, Stefanick ML, Van HL, Wallace RB, Whitlock E, Bassford T, Beresford SA, Black HR, Bonds DE, Brzyski RG, Caan B, Chlebowski RT, Cochrane B, Garland C, Gass M, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Judd H, Kooperberg CL, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Lewis CE, Limacher MC, Manson JE (2006) Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354(7):684–696CrossRefPubMed

73.

Trivedi D, Doll R, Khaw K (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326(7387):469CrossRefPubMedPubMedCentral

74.

Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR, Grant AM, Campbell MK, Anderson FH, Cooper C, Francis RM, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA (2012) Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). J Clin Endocrinol Metab 97(2):614–622. doi:10.1210/jc.2011-1309 CrossRefPubMed

75.

Fortmann SP, Burda BU, Senger CA, Lin J, Beil T, O’Connor E, Whitlock EP (2013) Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: a systematic evidence review for the U.S. preventive services task force. Evidence Report No. 108, AHRQ Publication No. 14-05199-EF-1. Agency for Healthcare Research and Quality, Rockville, MD

76.

Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, Zhang SM, Buring JE (2012) The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 33(1):159–171. doi:10.1016/j.cct.2011.09.009 CrossRefPubMed

77.

Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K, Virtamo J (2009) Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 101(18):1272–1279. doi:10.1093/jnci/djp260 CrossRefPubMedPubMedCentral

78.

Wehr E, Pilz S, Boehm BO, Marz W, Obermayer-Pietsch B (2010) Association of vitamin D status with serum androgen levels in men. Clin Endocrinol 73(2):243–248. doi:10.1111/j.1365-2265.2009.03777.x

79.

Mondul AM, Sampson JN, Moore SC, Weinstein SJ, Evans AM, Karoly ED, Virtamo J, Albanes D (2013) Metabolomic profile of response to supplementation with beta-carotene in the alpha-tocopherol, beta-carotene cancer prevention study. Am J Clin Nutr 98(2):488–493. doi:10.3945/ajcn.113.062778 CrossRefPubMedPubMedCentral

80.

Liu C, Russell RM, Wang XD (2003) Exposing ferrets to cigarette smoke and a pharmacological dose of beta-carotene supplementation enhance in vitro retinoic acid catabolism in lungs via induction of cytochrome P450 enzymes. J Nutr 133(1):173–179PubMed

81.

Paolini M, Antelli A, Pozzetti L, Spetlova D, Perocco P, Valgimigli L, Pedulli GF, Cantelli-Forti G (2001) Induction of cytochrome P450 enzymes and over-generation of oxygen radicals in beta-carotene supplemented rats. Carcinogenesis 22(9):1483–1495CrossRefPubMed

82.

Johnson CH, Slanar O, Krausz KW, Kang DW, Patterson AD, Kim JH, Luecke H, Gonzalez FJ, Idle JR (2012) Novel metabolites and roles for alpha-tocopherol in humans and mice discovered by mass spectrometry-based metabolomics. Am J Clin Nutr 96(4):818–830. doi:10.3945/ajcn.112.042929 CrossRefPubMedPubMedCentral

83.

Wong M, Lodge JK (2012) A metabolomic investigation of the effects of vitamin E supplementation in humans. Nutr Metab 9(1):1–9. doi:10.1186/1743-7075-9-110 CrossRef

84.

Nelson SM, Panagiotou OA, Anic GM, Mondul AM, Männistö S, Weinstein SJ, Albanes D (2016) A metabolomics analysis of serum 25-hydroxy-vitamin D in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int J Epidemiol (in press)

85.

Lloyd SM, Arnold J, Sreekumar A (2015) Metabolomic profiling of hormone-dependent cancers: a bird’s eye view. Trends Endocrinol Metab 26(9):477–485. doi:10.1016/j.tem.2015.07.001 CrossRefPubMedPubMedCentral

86.

Trock BJ (2011) Application of metabolomics to prostate cancer. Urol Oncol 29(5):572–581. doi:10.1016/j.urolonc.2011.08.002 CrossRefPubMedPubMedCentral

87.

Mondul AM, Moore SC, Weinstein SJ, Karoly ED, Sampson JN, Albanes D (2015) Metabolomic analysis of prostate cancer risk in a prospective cohort: the alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study. Int J Cancer 137(9):2124–2132. doi:10.1002/ijc.29576 CrossRefPubMedPubMedCentral

88.

Mondul AM, Moore SC, Weinstein SJ, Mannisto S, Sampson JN, Albanes D (2014) 1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling. Metabolomics 10(5):1036–1041. doi:10.1007/s11306-014-0643-0 CrossRefPubMedPubMedCentral

89.

Dell’ Antone P (2012) Energy metabolism in cancer cells: how to explain the Warburg and Crabtree effects? Med Hypotheses 79(3):388–392CrossRefPubMed

90.

Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140(1):49–61. doi:10.1016/j.cell.2009.11.027 CrossRefPubMedPubMedCentral

91.

Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279(15):2610–2623. doi:10.1111/j.1742-4658.2012.08644.x CrossRefPubMed

92.

Lucarelli G, Rutigliano M, Galleggiante V, Giglio A, Palazzo S, Ferro M, Simone C, Bettocchi C, Battaglia M, Ditonno P (2015) Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. Expert Rev Mol Diagn 15(9):1211–1224. doi:10.1586/14737159.2015.1069711 CrossRefPubMed

93.

Brandstedt J, Almquist M, Manjer J, Malm J (2012) Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control 23(8):1377–1385. doi:10.1007/s10552-012-9948-3 CrossRefPubMed

94.

Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, Hoffman AR, Barrett-Connor E, Orwoll E, Beer TM (2010) Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 21(8):1297–1303. doi:10.1007/s10552-010-9557-y CrossRefPubMedPubMedCentral

95.

Wong YY, Hyde Z, McCaul KA, Yeap BB, Golledge J, Hankey GJ, Flicker L (2014) In older men, lower plasma 25-hydroxyvitamin D is associated with reduced incidence of prostate, but not colorectal or lung cancer. PLoS One 9(6):e99954. doi:10.1371/journal.pone.0099954 CrossRefPubMedPubMedCentral

96.

Ordonez-Mena JM, Schottker B, Haug U, Muller H, Kohrle J, Schomburg L, Holleczek B, Brenner H (2013) Serum 25-hydroxyvitamin D and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol Biomarkers Prev 22(5):905–916. doi:10.1158/1055-9965.EPI-12-1332 CrossRefPubMed

97.

Meyer HE, Robsahm TE, Bjorge T, Brustad M, Blomhoff R (2013) Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr 97(1):147–154. doi:10.3945/ajcn.112.039222 CrossRefPubMed

98.

Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, Nimptsch K, Hollis BW, Dupre N, Platz EA, Stampfer MJ, Giovannucci E (2012) Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst 104(9):690–699. doi:10.1093/jnci/djs189 CrossRefPubMedPubMedCentral

99.

Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, Lane JA, Martin RM (2012) Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer 131(5):1187–1196. doi:10.1002/ijc.27327 CrossRefPubMed

100.

Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4(3):e103. doi:10.1371/journal.pmed.0040103 CrossRefPubMedPubMedCentral

101.

Ordonez-Mena JM, Schottker B, Fedirko V, Jenab M, Olsen A, Halkjaer J, Kampman E, de Groot L, Jansen E, Bueno-de-Mesquita HB, Peeters PH, Siganos G, Wilsgaard T, Perna L, Holleczek B, Pettersson-Kymmer U, Orfanos P, Trichopoulou A, Boffetta P, Brenner H (2016) Pre-diagnostic vitamin D concentrations and cancer risks in older individuals: an analysis of cohorts participating in the CHANCES consortium. Eur J Epidemiol 31(3):311–323. doi:10.1007/s10654-015-0040-7 CrossRefPubMed

102.

Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jorgensen T, Roswall N, Larsen SC, Linneberg A (2014) Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev 23(7):1220–1229. doi:10.1158/1055-9965.EPI-14-0007 CrossRefPubMed

103.

Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A, Holick MF (1998) Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9(4):425–432CrossRefPubMed

104.

Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR (2004) Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 89–90(1–5):533–537. doi:10.1016/j.jsbmb.2004.03.063 CrossRefPubMed

Titel: Vitamins, metabolomics, and prostate cancer
verfasst von: Alison M. Mondul
Stephanie J. Weinstein
Demetrius Albanes
Publikationsdatum: 23.06.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 6/2017
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-016-1878-3

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Vitamins, metabolomics, and prostate cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Feasibility and safety of augmented reality-assisted urological surgery using smartglass

SIU Newsletter - June 2017

Prostate cancer trends in Asia

Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract

Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report

90-Day complication rate in patients undergoing radical cystectomy with enhanced recovery protocol: a prospective cohort study

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie